Congestive heart failure in patients with chronic kidney disease and on dialysis

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Congestive heart failure (CHF) is highly prevalent in patients with end-stage renal disease (ESRD), representing a leading cause of mortality.
• Key risk factors for CHF in ESRD include hypertension, renal anemia, coronary artery disease, and potentially dialysis hypotension.
• Emerging evidence suggests lipid peroxidation and L-carnitine deficiency may play a role in CHF pathogenesis in ESRD patients.

Purpose of the Study:

• To review the current understanding of congestive heart failure (CHF) in end-stage renal disease (ESRD).
• To discuss risk factors, potential contributing mechanisms, and therapeutic options for CHF in the ESRD population.
• To highlight the underutilization of established medical therapies and the potential role of advanced interventions.

Main Methods:

• Literature review of studies investigating CHF in ESRD patients.
• Analysis of risk factors, including hypertension, renal anemia, and comorbid conditions.
• Evaluation of the impact of renal replacement therapy and pharmacologic interventions on CHF outcomes.

Main Results:

• Hypertension, renal anemia, and coronary artery disease are significant risk factors for CHF in ESRD.
• While renal replacement therapy may improve CHF symptoms, its effect on cardiovascular mortality remains uncertain.
• Certain drug therapies, such as angiotensin-converting enzyme inhibitors and beta-blockers, are underused in this patient population.

Conclusions:

• Effective management of CHF in ESRD requires addressing underlying risk factors and optimizing treatment strategies.
• Increased utilization of guideline-directed medical therapy is crucial for improving outcomes.
• Heart/kidney transplantation offers a potential therapeutic avenue for select advanced cases.